microangiopathy

The molecular biology of thrombotic microangiopathy.

unknown title 2011

About aHUS aHUS is a chronic, ultra-rare, and life-threatening disease in which a genetic deficiency in one or more complement regulatory genes causes life-long uncontrolled complement activation, resulting in complement-mediated thrombotic microangiopathy TMA, the formation of blood clots in small blood vessels throughout the body.

unknown title 2011

In November 2010, researchers at the American Society of Nephrology (ASN) annual meeting in Denver presented positive data from the Company's two Phase 2 26-week studies of eculizumab as a treatment for adult and adolescent patients with aHUS. aHUS is an ultra-rare, chronic and life-threatening disease in which uncontrolled complement activation causes blood clots in small blood vessels throughout the body (thrombotic microangiopathy, or TMA) leading to kidney failure, stroke, heart attack and death.

unknown title 2011

Massachusetts, United States of America In type 1 diabetes (T1D) vascular complications such as accelerated atherosclerosis and diffused macro -/microangiopathy are linked to chronic hyperglycemia with a mechanism that is not yet well understood.

PLoS ONE Alerts: New Articles Franco Folli et al. 2010

Fiorina P, Folli F, Bertuzzi F, Maffi P, Finzi G, et al. (2003) Long-term beneficial effect of islet transplantation on diabetic macro -/microangiopathy in type 1 diabetic kidney-transplanted patients.

PLoS ONE Alerts: New Articles Franco Folli et al. 2010

(CAPS) is an episodic, diffuse thrombotic microangiopathy observed in less than 1% of patients with antiphospholipid antibodies and is characterized by vascular occlusions involving three or more organ systems. 1 Typically preceded by triggering events, such as infection, trauma, or surgery, CAPS culminates in multiorgan system failure and is fatal in half of those in whom it develops.

Medlogs - Recent stories 2010

Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, et al. (2007) Prognostic value of anti-ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity.

PLoS ONE Alerts: New Articles Paul Coppo et al. 2010

In type 1 diabetes (T1D) vascular complications such as accelerated atherosclerosis and diffused macro -/microangiopathy are linked to chronic hyperglycemia with a mechanism that is not yet well understood.

PLoS ONE Alerts: New Articles Franco Folli et al. 2010

Abbreviation: TMA, thrombotic microangiopathy. doi: 10.1371/journal. pone.0010208.g002

PLoS ONE Alerts: New Articles Paul Coppo et al. 2010

Atkinson B, Montgomery R, Vesely S, Friedman K (2004) Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.

PLoS ONE Alerts: New Articles Paul Coppo et al. 2010